Dr. Jonathan Corren, MD
Allergy & Immunology (Clinical & Laboratory Immunology (Allergy & Immunology) Physician)
10780 Santa Monica Blvd, Suite 280
Los Angeles, CA 90025
Who else practices at this address →
Los Angeles County includes primary care (7% of residents) and mental health (13% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of California, San Diego School of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 268
Licensed in California since 1984, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: University of California, San Diego School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical & Laboratory Immunology (Allergy & Immunology) Physician primary
CA license G53016 (first issued 1984; current)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Jonathan Corren MD Inc (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 268
- Services billed
- 7,213
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Test for allergy using allergenic extract | 2,825 | 46 |
| Professional service for preparation and provision of 1 or more antigens | 1,930 | 42 |
| Professional service for multiple injections of allergen | 685 | 31 |
| Established patient office or other outpatient visit, 30-39 minutes | 246 | 162 |
| New patient office or other outpatient visit, 45-59 minutes | 69 | 69 |
| Established patient office or other outpatient visit, 20-29 minutes | 44 | 36 |
| Established patient office or other outpatient visit, 40-54 minutes | 35 | 29 |
| Test to measure rate of airflow | 32 | 29 |
| Telephone medical discussion with physician, 11-20 minutes | 17 | 14 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Los Angeles, CA | 67 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Los Angeles, CA | 47 |
| Azelastine Hcl Other prescribers in Los Angeles, CA | 47 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Los Angeles, CA | 45 |
| Prednisone Other prescribers in Los Angeles, CA | 30 |
| Arnuity Ellipta (fluticasone furoate) Other prescribers in Los Angeles, CA | 26 |
| Dupixent Syringe (dupilumab) Other prescribers in Los Angeles, CA | 19 |
| Diphenhydramine Hcl | 15 |
| Naltrexone Hcl Other prescribers in Los Angeles, CA | 14 |
| Famotidine Other prescribers in Los Angeles, CA | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 26 companies reported 131 payments worth $74,318 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $35,852 |
|---|---|
| Regeneron Healthcare Solutions, Inc. | $14,699 |
| Genzyme Corporation | $12,528 |
| GlaxoSmithKline, LLC. | $3,879 |
| Amgen Inc. | $3,278 |
| Eli Lilly and Company | $2,275 |
| AbbVie Inc. | $550 |
| Csl Behring | $171 |
| Compensation for services other than consulting (speaking, faculty) | $50,696 |
|---|---|
| Consulting Fee | $18,425 |
| Food and Beverage | $2,617 |
| Travel and Lodging | $2,580 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,240 |
| AstraZeneca Pharmaceuticals LP May 16, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,750 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,710 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,540 |
| Genzyme Corporation May 29, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,482 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,482 |
| Amgen Inc. Feb 4, 2025 | Consulting Fee | $3,175 |
All 50 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Dec 15, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,060 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,240 |
| AstraZeneca Pharmaceuticals LP Nov 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,710 |
| AstraZeneca Pharmaceuticals LP Nov 20, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Fresno, CA · in-kind Company’s descriptionSpeaker Expenses | $284 |
| AstraZeneca Pharmaceuticals LP Nov 20, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,060 |
| AstraZeneca Pharmaceuticals LP Nov 14, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,060 |
| Genzyme Corporation Nov 9, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Eli Lilly and Company Oct 8, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $700 |
| Genzyme Corporation Oct 1, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Sep 28, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Eli Lilly and Company Sep 23, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $700 |
| Genzyme Corporation Sep 11, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,165 |
| AbbVie Inc. Sep 10, 2025 | Consulting Fee | $550 |
| Eli Lilly and Company Sep 4, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $525 |
| Eli Lilly and Company Aug 26, 2025 | Consulting FeeCompany’s descriptionTHE REPORTED PAYMENT REFLECTS THE AMOUNT PROVIDED TO A THIRD PARTY EMPLOYER OR INSTITUTION IN CONNECTION WITH RESEARCH RELATED SERVICES PROVIDED BY THE COVERED RECIPIENT. LILLY DOES NOT KNOW HOW MUCH, IF ANY, OF THIS AMOUNT WAS ACTUALLY RECEIVED BY THE COVERED RECIPIENT. | $350 |
| AstraZeneca Pharmaceuticals LP Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Aug 5, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| AstraZeneca Pharmaceuticals LP Jul 29, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $100 |
| Regeneron Healthcare Solutions, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,482 |
| GlaxoSmithKline, LLC. Jun 25, 2025 | Consulting Fee | $2,600 |
| Regeneron Healthcare Solutions, Inc. Jun 24, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,055 |
| Genzyme Corporation Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| Genzyme Corporation Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $250 |
| Genzyme Corporation May 29, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $3,482 |
| AstraZeneca Pharmaceuticals LP May 20, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| Genzyme Corporation May 19, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology · in-kind Company’s descriptionIf more than one clinical reprint is received on the same day, the reported transfer of value will reflect the aggregate total. | $500 |
| GlaxoSmithKline, LLC. May 17, 2025 | Travel and Lodging travel to SanFrancisco, CA · in-kind | $458 |
| AstraZeneca Pharmaceuticals LP May 16, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,750 |
| AstraZeneca Pharmaceuticals LP May 14, 2025 | Consulting Fee TEZSPIRE · Respiratory | $1,611 |
| GlaxoSmithKline, LLC. Apr 25, 2025 | Consulting Fee | $650 |
| AstraZeneca Pharmaceuticals LP Apr 23, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| AstraZeneca Pharmaceuticals LP Apr 18, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,600 |
| AstraZeneca Pharmaceuticals LP Apr 17, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Pittsburgh, PA · in-kind Company’s descriptionSpeaker Expenses | $544 |
| AstraZeneca Pharmaceuticals LP Apr 17, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Pittsburgh, PA · in-kind Company’s descriptionSpeaker Expenses | $497 |
| AstraZeneca Pharmaceuticals LP Apr 17, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to Pittsburgh, PA · in-kind Company’s descriptionSpeaker Expenses | $438 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,078 |
| Regeneron Healthcare Solutions, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $1,488 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $3,540 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $2,360 |
| Regeneron Healthcare Solutions, Inc. Apr 4, 2025 | Consulting Fee DUPIXENT · IMMUNOLOGY AND INFLAMMATION | $590 |
| AstraZeneca Pharmaceuticals LP Mar 25, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $4,300 |
| Genzyme Corporation Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) DUPIXENT · Immunology | $2,216 |
| AstraZeneca Pharmaceuticals LP Mar 7, 2025 | Consulting Fee | $537 |
| AstraZeneca Pharmaceuticals LP Mar 2, 2025 | Travel and Lodging TEZSPIRE · Respiratory · travel to San Diego, CA · in-kind Company’s descriptionSpeaker Expenses | $360 |
| AstraZeneca Pharmaceuticals LP Feb 18, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Amgen Inc. Feb 4, 2025 | Consulting Fee | $3,175 |
| AstraZeneca Pharmaceuticals LP Jan 10, 2025 | Consulting FeeCompany’s descriptionResearch Related Service | $537 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $7,953 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria
Amgen Inc. - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.